Methoxyalkyl thiazoles: A novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase

R. M. McMillan, Stephen J. Foster(UNSW Sydney), John F. Kingston, T. G. C. Bird, G. C. CRAWLEY, Martin P. Edwards(Pfizer (United States)), J.‐M. GIRODEAU

Inflammation Research

September 1, 1991

10.1007/bf01993252

Cited by 8

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

|Journal of Medicinal Chemistry|2011|924

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

|Journal of Medicinal Chemistry|2014|587

Using the Golden Triangle to optimize clearance and oral absorption

|Bioorganic & Medicinal Chemistry Letters|2009|382

Lipophilic Efficiency as an Important Metric in Drug Design

|Journal of Medicinal Chemistry|2018|340

Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis

|Bioorganic & Medicinal Chemistry Letters|2009|269